DENVER, June 17 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, announced today the appointment of Barry L. Molk, M.D., F.A.C.C., and Charles H. Miranda, M.D., F.A.C.P., F.A.A.P., to its scientific advisory board.
Drs. Molk and Miranda join Luis Lopez, M.D., Corgenix Chairman and Chief Medical Officer, expanding the number of scientific advisory board members to three.
"These two individuals bring a wealth of knowledge and expertise to our organization," said Douglass Simpson, Corgenix' President and Chief Executive Officer. "Their appointment strengthens the clinical and scientific guidance required for the successful development, manufacturing and marketing of our diagnostic testing products."
Dr. Molk has been affiliated with Aurora Denver Cardiology Associates since 1976 and has served as Chief of Cardiology at Sky Ridge Medical Center since 2003. He is board certified in internal medicine and cardiovascular diseases and is also a Fellow of the American College of Cardiology (F.A.C.C.).
After receiving his medical degree from the University of Colorado Health Sciences Center (UCHSC), Dr. Molk completed his residency training at Baylor Affiliated Hospitals and UCHSC, and is fellowship trained in cardiology from UCHSC. He maintains a teaching appointment as Associate Clinical Professor of Medicine, UCHSC.
Dr. Miranda is currently in private practice in internal medicine and pediatrics at South Denver Internal Medicine and Pediatrics, P.C. in Denver. Previously, he practiced internal medicine and pediatrics for 10 years at the world-renowned Texas Medical Center in Houston. Miranda is board certified by the American Board of Internal Medicine and the American Board of Pediatrics. He is a Fellow of the American Academy of Pediatrics (F.A.A.P.) and the American College of Physicians (F.A.C.P.).
Dr. Miranda received his medical degree from the University of California, San Francisco (UCSF). He completed specialty training in both internal medicine and pediatrics at Baylor College of Medicine in Houston, Texas. He is also a clinical instructor in the department of medicine at UCHSC.
Corgenix periodically draws on the expertise of advisors and consultants in fields related to its technology and markets. These members are available to Corgenix as needed on an individual basis to provide advice with respect to clinical medicine and other matters requiring scientific expertise. Non-employee members of the scientific advisory board are compensated for their participation.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at http://www.corgenix.com.
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
|SOURCE Corgenix Medical Corporation|
Copyright©2008 PR Newswire.
All rights reserved